Analysts Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) PT at $25.17

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has earned an average rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $25.17.

CNTA has been the topic of a number of research reports. BMO Capital Markets raised their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. B. Riley initiated coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. Guggenheim boosted their price objective on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Finally, Jefferies Financial Group upped their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA opened at $16.29 on Monday. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29. Centessa Pharmaceuticals has a 1-year low of $5.58 and a 1-year high of $17.59. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -11.47 and a beta of 1.46. The business’s fifty day moving average price is $14.50 and its 200-day moving average price is $11.28.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). On average, equities analysts predict that Centessa Pharmaceuticals will post -1.68 earnings per share for the current year.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 12,198 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total transaction of $148,449.66. Following the sale, the insider now directly owns 241,171 shares of the company’s stock, valued at $2,935,051.07. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 12,198 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total value of $148,449.66. Following the completion of the transaction, the insider now directly owns 241,171 shares in the company, valued at $2,935,051.07. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total transaction of $51,362.08. Following the sale, the chief executive officer now owns 827,755 shares in the company, valued at approximately $10,197,941.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 288,492 shares of company stock valued at $4,641,902. Company insiders own 11.59% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds have recently bought and sold shares of CNTA. GAMMA Investing LLC grew its position in shares of Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in Centessa Pharmaceuticals during the 2nd quarter valued at approximately $4,064,000. Perceptive Advisors LLC increased its stake in Centessa Pharmaceuticals by 27.6% in the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock worth $35,518,000 after acquiring an additional 850,000 shares during the last quarter. Quarry LP increased its stake in Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after acquiring an additional 3,108 shares during the last quarter. Finally, Driehaus Capital Management LLC raised its holdings in shares of Centessa Pharmaceuticals by 89.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock worth $18,891,000 after acquiring an additional 987,997 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.